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AIMS
Although oral anticoagulants (OACs) are effective in preventing stroke in older people with atrial fibrillation (AF), they are often
underused in this particularly high-risk population. The aim of the present study was to assess the appropriateness of OAC
prescription and its associated factors in hospitalized patients aged 65 years or older.
METHODS
Data were obtained from the retrospective phase of Simulation-based Technologies to Improve the Appropriate Use of Oral
Anticoagulants in Hospitalized Elderly Patients With Atrial Fibrillation (SIM-AF) study, held in 32 Italian internal medicine and
geriatric wards. The appropriateness of OAC prescription was assessed, grouping patients in those who were and were not
prescribed OACs at hospital discharge. Multivariable logistic regression was used to establish factors independently associated
with the appropriateness of OAC prescription.
RESULTS
A total of 328 patients were included in the retrospective phase of the study. Of these, almost 44% (N = 143) were inappropriately
prescribed OACs, being mainly underprescribed or prescribed an inappropriate antithrombotic drug (N = 88). Among the
patients prescribed OACs (N = 221), errors in the prescribed doses were the most frequent cause of inappropriate use (N = 55).
Factors associated with a higher degree of patient frailty were inversely associated with the appropriateness of OAC prescription.
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CONCLUSIONS
In hospitalized older patients with AF, there is still a high prevalence of inappropriate OAC prescribing. Characteristics usually
related to frailty are associated with the inappropriate prescribing. These findings point to the need for targeted interventions
designed for internists and geriatricians, aimed at improving the appropriate prescribing of OACs in this complex and high-risk
population.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Oral anticoagulants are the recommended choice for preventing stroke in patients with atrial fibrillation, including in
older people.
• The available data on oral anticoagulant prescriptions are mainly provided within the framework of cardiology settings.
WHAT THIS STUDY ADDS
• In older patients with atrial fibrillation who are hospitalized in internal medicine and geriatric wards, there is still a high
prevalence of inappropriate oral anticoagulant prescription.
• Inappropriate oral anticoagulant prescribing in older people is mainly related to their underuse or to errors in the doses
prescribed.
• Characteristics usually related to frailty are associated with their inappropriate prescribing.
• Targeted interventions aimed at improving the appropriate prescribing of oral anticoagulants in this complex and high-
risk population are needed.
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhyth-
mia, the prevalence of which increases with age [1]. Vitamin
K antagonists (VKAs) have long been the only available oral
anticoagulants (OACs) in patients with nonvalvular AF for
the prevention of stroke [2]. The narrow therapeutic index,
drug–drug interactions and the need for close monitoring
were the main disadvantages of VKAs. In order to overcome
these problems, the nonvitamin K antagonist oral anticoagu-
lants (NOACs) have been introduced onto the market, with
the advantages of allowing a fixed-dose regimen and no need
of regular anticoagulationmonitoring. NOACs, including the
direct thrombin inhibitor, dabigatran, and the factor Xa
inhibitors, apixaban, edoxaban and rivaroxaban, have
been demonstrated to be effective in reducing the incidence
of stroke or systemic embolic events, and are safer than the
most-used VKA, warfarin [3]. Thus, they represent the
currently recommended choice of agent for preventing stroke
in patients with AF, including in older people [4].
Notwithstanding these recommendations, various studies
have highlighted the frequent underuse of OACs in up to
40–60% of older people with AF [5, 6], even though the ben-
efit has been widely demonstrated in these patients [7, 8]. In
older patients, OAC underuse has been associated with the
prescription of antiplatelet drugs [6, 9]. However, antiplatelet
agents alone have a limited role in reducing the thromboem-
bolic risk in AF, and also are no safer than OACs in terms of
the risk of bleeding, especially in the elderly [10].
Furthermore, to date, most of the available data on OAC
prescriptions have been provided within the framework of
cardiology settings, and in younger patients. The only data
on OAC prescriptions in older people with AF who are
hospitalized in internal medicine and geriatric wards comes
from the REgistro POliterapie-SIMI (REPOSI) register, which
confirmed that the majority of them had been undertreated
or inappropriately treated with antiplatelet drugs, both before
[11] and after [12] the introduction of NOACs onto the market.
With this background, the objectives of the present study
were: (i) to assess the appropriateness of OAC therapy at
hospital discharge, according to criteria set up by means of a
revision of the published literature; and (ii) to identify the
factors associated with the appropriate prescription of OACs
by 32 Italian internal medicine and geriatric wards in a cohort
of older patients retrospectively included in the Simulation-
based Technologies to Improve the Appropriate Use of Oral
Anticoagulants in Hospitalized Elderly Patients With Atrial
Fibrillation (SIM-AF) study.
Methods
Setting and data collection
The study was conducted in 32 Italian internal medicine and
geriatric wards participating in the SIM-AF study
(ClinicalTrials.gov #NCT03188211), a cluster randomized
controlled trial aimed at assessing the effectiveness of
simulation-based technologies, in order to improve the
appropriate use of OACs in hospitalized older patients with
nonvalvular AF. The wards participating in the SIM-AF study
were recruited on a voluntary basis among the Italian internal
medicine and geriatric wards belonging to the REPOSI
register network [13]. A detailed description of the study
protocol has been published previously [14]. Briefly, the
SIM-AF study was divided in a retrospective pre-intervention
phase, which preceded the randomization of wards to the
intervention (educational programme with simulation
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technologies) or control (current clinical practice), and an
in-hospital post-intervention prospective phase. In the
pre-intervention observational phase, every ward retrospec-
tively analysed the medical records of at least 10 AF
patients aged 65 years or older, consecutively admitted
over the previous 8 months in their hospital wards (from
October 2016 up to May 2017). The principal data
collected included sociodemographic characteristics, labo-
ratory parameters [such as serum creatinine, alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST)], pharmacological therapies and previous diseases
(such as stroke, major bleeding or coronary artery bypass
graft) at hospital discharge.
For the purpose of the present study, patients included in
the observational retrospective phase of SIM-AF were consid-
ered for analysis. To assess the prescription of OACs, we used
the following Anatomical Therapeutic Chemical classifica-
tion system (ATC) codes: B01AA03 (warfarin), B01AA07
(acenocoumarol), B01AF01 (rivaroxaban), B01AF02
(apixaban), B01AF03 (edoxaban), B01AE07 (dabigatran).
The SIM-AF project was approved by the ethics committee
of the Ca0 Granda Maggiore Policlinico Hospital Foundation
and then by the local ethical committees of the participating
centres. The study was conducted according to Good Clinical
Practice and the Declaration of Helsinki.
Criteria for prescription appropriateness
By means of a revision of the published literature, we consid-
ered the European Society of Cardiology (ESC) guidelines [4],
the Beers criteria [15] and the European Public Assessment
Report (EPAR) – summary of products characteristics [16] in
order to define whether or not the prescribed drug was
appropriate. Table S1 presents the criteria we employed in
the study. OAC appropriateness was first defined by looking
at the type and then at the dose of the drug chosen. To assess
OAC therapy appropriateness, patients were grouped into
those who were and were not prescribed OACs at the time
of hospital discharge. When a patient was labelled as ‘not
appropriate’ for one criterion, his/her assessment on prescrip-
tion appropriateness was stopped and thus he/she was
included in the inappropriately prescribed group.
The ESC guidelines recommend that the stroke risk in AF
patients is estimated through the CHA2DS2-VASc score [4].
In general, men with a CHA2DS2-VASc score of 1 or more,
and women with a score of 2 or more were considered to be
at moderate or high risk, and likely to benefit from OAC
therapy. Thus, they were considered as ‘appropriate’ for non-
prescription only if they reported a contraindication to OAC
treatment, such as a previous adverse drug reaction or bleed,
risk of poor drug adherence or potential drug–drug interac-
tion. As we included people aged 65 years or more, no low-
risk patients (CHA2DS2-VASc score of 0) were represented in
this cohort. Men with a CHA2DS2-VASc score ≥1, and women
with a score ≥2 who had been prescribed an antithrombotic
agent other than an OAC (such as an antiplatelet drug or hep-
arin) were considered as ‘not appropriate’, owing to the
wrong choice of drug prescribed. A combination of an OAC
with an antiplatelet agent (aspirin or clopidogrel) were
considered as ‘appropriate’ only if prescribed within the
period of 1–12 months after an elective coronary stenting [4].
With reference to the dose of OACs, the recommended
dose for dabigatran is 150 mg twice daily, rivaroxaban
20 mg once daily, apixaban 5 mg twice daily and edoxaban
60 mg once daily; for warfarin, this depends on the
international normalized ratio (INR) and the time in the
therapeutic range (TTR). Given that the INR and TTR were
assessed only at discharge, we assumed that all of the warfarin
and acenocoumarol prescriptions were ‘appropriate’. As
presented in Table S1, the recommended and thus appropri-
ate adjustments for NOAC doses based on the presence of
chronic kidney disease [as assessed by high values of serum
creatinine or creatinine clearance (CrCl)], older age, specific
drug–drug interactions, high risk of gastrointestinal bleeding
[as assessed by means of a HAS-BLED (Hypertension, Abnor-
mal Renal/Liver Function, Stroke, Bleeding History or Predis-
position, Labile INR, Elderly, Drugs/Alcohol Concomitantly)
score ≥3 [4] and/or the presence of previous gastrointestinal
bleeding] and severe hepatic impairment (as assessed by the
presence of liver failure and/or values of ALT ≥41 U/l–1 and
AST ≥33 U l–1 [17]). Patients with missing values of serum
creatinine, CrCl or AST plus ALT were considered ‘not
assessable’. Finally, contraindicated and major drug–drug
interactions were assessed for NOACs according to the
INTERCheck® software database, routinely updated by the
IRCCS – Istituto di Ricerche Farmacologiche “Mario Negri”
and validated in the hospital setting [18].
Statistical analysis
Continuous variables were expressed as median and
interquartile range (IQR). Comparisons between groups were
performed using the Mann–Whitney U test. Categorical
variables were expressed as counts and percentages and
compared with the nonprescription chi-square test. To
establish factors independently associated with appropriate-
ness of OAC prescription or nonprescription, a logistic regres-
sion analysis was performed. All variables with a P < 0.20 at
baseline for comparison between appropriate and inappro-
priate patients underwent univariate analysis. All variables
with a P < 0.10 at univariate analysis were entered into the
multivariable models. Two multivariable models were set up
in order to consider the body mass index (BMI) both as a
continuous variable (first model) or as classes according to
World Health Organization definition (second model). A
two-sided P-value <0.05 was considered to be statistically
significant. All analyses were performed using SPSS v. 24.0
(IBM, New York, NY, USA).
Nomenclature of targets and ligands
Key ligands in this article are hyperlinked to corresponding
entries in http://www.guidetopharmacology.org, the com-
mon portal for data from the IUPHAR/BPS Guide to PHAR-
MACOLOGY [19].
Results
Overall, 328 older patients were included in the study by 32
internal medicine and geriatric wards at hospital discharge.
Among them, 221 (67.4%) were prescribed with OACs at
hospital discharge. Our previous work reported the main
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characteristics of prescribed and nonprescribed patients
in this cohort [14]. Briefly, most of the patients prescribed
OACs (52%) were men, with a mean age of 83 years. Themost
prescribed NOAC was apixaban (46.5%) [14].
In the present analysis, out of the 328 patients, 172
(52.4%) were considered as appropriately prescribed OACs,
whereas 143 (43.6%) were not appropriately prescribed.
Table 1 shows the profiles of the appropriateness of OAC pre-
scription in prescribed and non prescribed patients at hospi-
tal discharge. Of those prescribed OACs, in 153 cases
(69.2%) this was appropriate, in 55 cases (24.9%) it was not
appropriate and in 13 cases (5.9%) this was not assessable.
Among those that were not appropriate, most (43/55,
78.2%) presented errors in the dose prescribed (i.e. full dose
when there was an indication for a reduction, or a reduced
dose when there was no indication for a reduction), the ma-
jority being in the reduced dose group (32/43 patients,
74.4%). Among patients with no OAC prescription, this was
appropriate in only 19 cases (18%) as, even though they were
at high risk of thromboembolic events, they had a contraindi-
cation for the OAC treatment (Table S1). However, most
patients (82%) were not prescribed an OAC but with another,
inappropriate antithrombotic drug (i.e. the wrong choice of
drug). Only two patients presented a risk for a drug–drug
interaction, both being prescribed apixaban together with
clarithromycin or ritonavir, respectively.
Table 1






APPROPRIATE 153 (69.2) 19 (18)
a) CHA2DS2-VASc ≥1 (men) and ≥2 (women) but with contraindication for OAC – 19







NOT APPROPRIATE 55 (24.9) 88 (82)
a) CHA2DS2-VASc ≥1 (men) and ≥2 (women) and no contraindication for OAC – –
b) CHA2DS2-VASc ≥1 (men) and ≥2 (women) with other antithrombotic monotherapy
(underprescription or wrong choice of drug)
– 88
c) Dual/triple therapy without elective coronary stenting 12 –
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Table 2 reports themain characteristics of patients according
to the appropriateness of OAC therapy at hospital discharge.
Compared with patients for whom this was not appropriate,
those appropriate for OAC prescription were younger, had a
higher BMI and were more likely to have a history of acute cor-
onary syndrome but were less likely to have a history of falls, he-
patic or vascular disease (defined as a previous history of acute
coronary syndrome or peripheral artery disease), or a risk of
bleeding. Table 3 shows the results of univariate and multivari-
able logistic regression analyses. In the multivariable analysis,
overweight (P = 0.04) and having undergone a coronary artery
bypass graft (P = 0.01) were independently associated with the
appropriate prescription of OACs, whereas a history of falls (P
< 0.05), vascular disease (P = 0.002) and liver disease (P = 0.02)
were inversely associated.
Discussion
The present study evaluated the appropriateness of OAC
therapy in older patients with AF who have been hospitalized
in internal medicine and geriatric wards and enrolled in the
Table 2
Characteristics of patients at hospital discharge according to the appropriateness of oral anticoagulant prescription
Appropriateness
No N = 143 Yes N = 172 P-value
Age, years [median (IQR)] 84 [79–88] 82 [77–87] 0.033
Age classes, n (%) 0.108
65–74 years 18 (12.6) 29 (16.9)
75–84 years 56 (39.2) 80 (46.5)
≥85 years 69 (48.3) 63 (36.6)
Female gender, n (%) 76 (53.1) 84 (48.8) 0.446
Living status, n (%) 0.312
Alone 9 (6.4) 9 (5.2)
Family 106 (75.2) 119 (69.2)
Institutionalized 26 (18.4) 44 (25.6)
Marital status, n (%) 0.488
Alone 14 (10.0) 12 (7.0)
Married 65 (46.4) 89 (52.0)
Divorced/widowed 61 (43.6) 70 (40.9)
Education status, n (%) 0.351
None/primary 64 (45.1) 77 (45.0)
Secondary 68 (47.9) 88 (51.5)
Higher degree 10 (7.0) 6 (3.5)
History of falls, n (%) 35 (24.5) 24 (14.0) 0.017
Current smoking, n (%) 33 (23.1) 31 (18.0) 0.267
Alcohol use, n (%) 22 (15.4) 19 (11.0) 0.255
ALT, UI l–1 [median (IQR)] 277 18 [13–30] 19 [14–25] 0.875
AST, UI l–1 [median (IQR)] 253 22 [15–31] 20 [15–29] 0.422
CrCl, ml/min–1 (median [IQR]) 295 44.4 [30.1–65.1] 44.7 [31.8–62.3] 0.944
CrCl categories, n (%) 295 0.412
≥60 ml min–1 39 (29.5) 45 (27.6)
30–59 ml min–1 61 (46.2) 87 (53.4)
<30 ml min–1 32 (24.2) 31 (19.0)
BMI, kg m–2 (median [IQR]) 297 24.2 [22.2–27.3] 25.7 [22.7–28.9] 0.038
(continues)
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SIM-AF study. Almost 44% of patients were inappropriately
prescribed OACs, beingmainly underprescribed or prescribed
a wrong antithrombotic drug. Among patients prescribed
OACs, dosage errors were the most frequent cause of inappro-
priate prescription. Factors associated with a higher perceived
frailty such as older age, a history of falls, liver disease and
vascular disease were inversely associated with the appropri-
ateness of OAC prescription.
Many studies have shown that OACs are underprescribed in
older people with AF, and the use of antiplatelet agents is
linked to a high likelihood of OAC underuse [5, 6, 11,
12]. Our study confirmed the underprescription of OACs in
favour of other antithrombotic therapy among hospitalized
older patients with AF. The under- or nonprescription of
OACs in older patients with AF represents a clinical paradox:
the subjects who might benefit the most from such a therapy
are those who are either undertreated or prescribed inappro-
priate antiplatelet agents. Indeed, older patients present
peculiarities and clinical characteristics that make the thera-
peutic decision-making process highly challenging for
clinicians, in that they are frailer, affected by multiple comor-




No N = 143 Yes N = 172 P-value
BMI categories, n (%) 0.027
Underweight 7 (5.3) 2 (1.2)
Normal weight 69 (51.9) 67 (40.9)
Overweight 42 (31.6) 69 (42.1)
Obesity 15 (11.3) 26 (15.9)
SBP, mmHg [median (IQR)] 312 120 [110–130] 120 [110–130] 0.688
DBP, mmHg [median (IQR)] 312 70 [60–80] 70 [60–80] 0.947
Type of AF, n (%) 0.083
Paroxysmal 36 (25.2) 50 (29.1)
Persistent 77 (53.8) 97 (56.4)
Permanent 16 (11.2) 20 (11.6)
Unknown 14 (9.8) 5 (2.9)
Stroke/TIA, n (%) 34 (23.8) 30 (17.4) 0.164
Hypertension, n (%) 105 (73.4) 139 (80.8) 0.118
Diabetes mellitus, n (%) 35 (24.5) 52 (30.2) 0.255
CKD, n (%) 61 (43.0) 85 (49.7) 0.233
Neoplasm, n (%) 31 (21.7) 27 (15.7) 0.173
Pulmonary disease, n (%) 38 (26.6) 56 (32.6) 0.248
Heart failure, n (%) 80 (55.9) 103 (59.9) 0.480
Vascular disease, n (%) 63 (44.1) 55 (32.0) 0.027
PTCA/CABG, n (%) 15 (10.5) 30 (17.4) 0.079
Liver disease, n (%) 18 (12.6) 11 (6.4) 0.058
Previous major bleeding, n (%) 19 (13.3) 16 (9.3) 0.263
Dementia, n (%) 37 (25.9) 30 (17.4) 0.069
Depression, n (%) 21 (14.7) 24 (14.0) 0.853
Polypharmacy, n (%) 107 (74.8) 139 (80.8) 0.201
HAS-BLED [median (IQR)] 3 [2–4] 2 [2–3] 0.015
CHA2DS2-VASc [median (IQR)] 5 [4–6] 5 [4–6] 0.271
AF, atrial fibrillation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CABG, coronary artery bypass graft;
CKD, chronic kidney disease; CrClm creatinine clearance; DBP, diastolic blood pressure; HAS-BLED, Hypertension, Abnormal Renal/Liver Function,
Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; IQR, interquartile range; PTCA, percutaneous translu-
minal coronary angioplasty; SBP, systolic blood pressure; TIA, transient ischaemic attack
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high risk of bleeding [22]. Moreover, in a noncardiological set-
ting, poor knowledge of the guidelines could have a negative
impact on OAC prescription in this at-risk population. A re-
cent study confirmed that, even if the use of anticoagulant
drugs increased over time in older AF patients, the non-use
of anticoagulants was due to a high bleeding risk in these pa-
tients [23], even though an overall positive assessment of the
risk/benefit ratio for these drugs has been established in this
population [24].
Among patients prescribed OACs, errors in the doses used
were the most frequent cause of inappropriate prescription.
Even if the NOACs are marketed as having simplified dosing
as compared with that for warfarin, the appropriate dose of
these agents is dependent on several patient-specific factors,
such as age, weight, baseline renal and hepatic impairment
and concomitant drug use [16]. As shown in a previous study,
in which the majority of patients on an inappropriate dose of
OAC were found to be on a lower dose than recommended
[25], we also found that most errors were due to unnecessarily
reduced doses. This is probably due to the fact that it has been
shown that lower doses are associated with a reduction in the
risk of major bleeding [26]. Moreover, given that an antidote
for NOACs is available only for dabigatran, prescribing lower
doses makes clinicians more confident about the safety of the
prescription. Given the complexity of dose adjustments and
the potential adverse events that may derive from inappropri-
ate dosing, it is highly recommended that clinicians take into
account patients’ baseline clinical characteristics and the
drugs they are taking before starting on a NOAC. This also
means that, before prescribing a NOAC, it is essential to con-
sider conducting some liver function tests, such as ALT and
AST levels, which are often omitted or not routinely collected
in internal medicine and geriatric wards, by contrast with
other tests, such as the measurement of haemoglobin or se-
rum creatinine levels.
Finally, our evaluation of factors associated with the ap-
propriateness of OAC prescription highlighted that frailer
patients are usually inappropriately prescribed OACs. These
findings are in line with our previous results [14] and those
coming from a sub-analysis from the Prevention of throm-
boembolic events – European Registry in Atrial Fibrillation
(PREFER-AF) study [27]. A history of falls was inversely asso-
ciated with the appropriate use of OACs. Among the 35 pa-
tients with a history of falls who were inappropriately
prescribed, approximately one-third were prescribed no an-
tithrombotic agent (data not shown). This was probably
due to the fear of treating older patients who had already
undergone a traumatic event leading to bleeding. By con-
trast, a third of those who were not prescribed OAC were in-
appropriately prescribed an antiplatelet drug (data not
shown). It is known that anticoagulation is often avoided
in patients with AF who are at an increased risk of falling,
but a recent study showed that, even in these patients, the
NOAC edoxaban resulted in a greater absolute reduction in
the risk of severe bleeding events and all-cause mortality
compared with warfarin [28]. In this study, the concomitant
presence of vascular disease or peripheral artery disease was
associated with inappropriate prescription of OACs. This is
an important issue, as recent ESC guidelines for peripheral
arterial diseases recommended that only OACs should be
prescribed in AF patients with these diseases [29].
Table 3
Results from univariate and multivariable logistic regression analyses
for the appropriateness of oral anticoagulant prescribing
OR 95% CI P-value
Univariate analysis
Age (year) 0.97 0.94–1.00 0.030
History of falls 0.50 0.28–0.89 0.018
BMI (kg m–2) 1.07 1.01–1.12 0.020
BMI categories
Underweight 0.29 0.06–1.47 0.136
Normal weight (ref.) – – –
Overweight 1.69 1.02–2.82 0.043
Obesity 1.79 0.87–3.66 0.114
Type of AF
Paroxysmal (ref.) – – –
Persistent 0.91 0.54–1.53 0.714
Permanent 0.90 0.41–1.97 0.792
Unknown 0.26 0.09–0.78 0.016
Stroke/TIA 0.68 0.39–1.18 0.166
Hypertension 1.52 0.90–2.59 0.120
Neoplasm 0.67 0.38–1.19 0.174
PTCA/CABG 1.80 0.93–3.50 0.082
Vascular disease 0.60 0.38–0.95 0.028
Liver disease 0.47 0.22–1.04 0.063
Dementia 0.61 0.35–1.04 0.070
Multivariable analysis: Model 1
History of falls 0.53 0.29–0.97 0.038
BMI (per kg m–2) 1.08 1.02–1.14 0.010
PTCA/CABG 2.67 1.25–5.70 0.011
Vascular disease 0.42 0.25–0.72 0.002
Liver disease 0.36 0.16–0.83 0.016
Multivariable analysis: Model 2
History of falls 0.55 0.30–1.01 0.056
BMI categories
Underweight 0.31 0.60–1.59 0.161
Normal weight (ref.) – – –
Overweight 1.76 1.04–3.00 0.037
Obesity 2.72 0.97–4.40 0.060
PTCA/CABG 2.72 1.27–5.85 0.010
Vascular disease 0.42 0.25–0.72 0.002
Liver disease 0.37 0.16–0.84 0.018
AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery
bypass graft; CI, confidence interval; OR, odds ratio; PTCA, percu-
taneous transluminal coronary angioplasty; ref., reference; TIA,
transient ischaemic attack
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Limitations and strengths
The present study had some limitations. The main limitation
was the overall small number of subjects involved, which
would have affected the multivariable analysis results for
some variables (i.e. age). Moreover, some laboratory values,
such as AST and ALT levels, were missing. Furthermore, we
did not collect repeated measures of INR and TTR. Finally,
we were not able to follow up these patients after hospital
discharge. Despite all these limitations, our data provided a
reliable view on current clinical practice and on the
appropriateness of OAC prescribing in older AF patients
hospitalized in a large sample of Italian internal medicine
and geriatric wards.
Conclusions
The study emphasizes that there is still a high prevalence of
inappropriate prescribing of OACs in hospitalized older pa-
tients with AF, and that characteristics linked to frailty are as-
sociated with the inappropriate prescribing of this class of
drugs. These findings call for targeted interventions by clini-
cians, aimed at both obtaining a deeper knowledge of the
benefits and risks of OACs, and also improving the appropri-
ate prescribing of these drugs in the older population with AF,
thus increasing their use and decreasing errors in the doses
prescribed. For this purpose, we hope that the SIM-AF trial
will demonstrate that an educational simulation-based inter-
vention will be effective at improving the appropriateness of
OAC prescription in older patients with AF who are admitted
to internal medicine and geriatric hospital wards and thus
perhaps reduce the risk of thromboembolic complications
in this high-risk population.
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